Ma ka lā 5 Iulai, ua hoʻokumu ʻo Novo Nordisk i kahi hoʻokolohua hoʻokolohua hoʻokolohua III o CagriSema injection ma Kina, ʻo ke kumu o ka hoʻohālikelike ʻana i ka palekana a me ka pono o ka injection CagriSema me ka semeglutide i nā maʻi obese a overweight ma Kina.
ʻO CagriSema injection kahi lāʻau hoʻohui lōʻihi ma lalo o ka hoʻomohala ʻana e Novo Nordisk, ʻo nā mea nui ʻo GLP-1 (glucagon-like peptide-1) receptor agonist smeglutide a me kahi amylin analog cagrilintide lōʻihi.Hiki ke lawelawe ʻia ma lalo o ka ʻili ʻo CagriSema i hoʻokahi pule.
ʻO ka pahuhopu nui e hoʻohālikelike iā CagriSema (2.4 mg / 2.4 mg) me ka semeglutide a i ʻole placebo i hoʻokahi pule ma lalo o ka ʻili.Ua hoʻolaha ʻo Novo Nordisk i nā hopena o ka hoʻāʻo ʻana o CagriSema no ka mālama ʻana i ka maʻi diabetes 2, kahi i hōʻike ʻia ʻoi aku ka maikaʻi o ka hopena hypoglycemic o CagriSema ma mua o ka semeglutide, a kokoke i 90% o nā kumuhana i hoʻokō i ka pahuhopu HbA1c.
Ua hōʻike ka ʻikepili i ka hoʻohui ʻana i ka hopena hypoglycemic koʻikoʻi, ma ke ʻano o ka pohō kaumaha, ʻoi aku ka nui o ka hoʻoiho ʻana o CagriSema i ka semeglutide (5.1%) a me ka cagrilintide (8.1%) me ka pohō kaumaha o 15.6%.
ʻO ka lāʻau lapaʻau hou ʻo Tirzepatide ka mea mua i ʻae ʻia i kēlā me kēia pule GIP/GLP-1 receptor agonist.Hoʻohui ia i nā hopena o ʻelua incretins i loko o kahi mole hoʻokahi i hoʻopaʻa ʻia i hoʻokahi pule i ka pule a he papa hou o nā lāʻau lapaʻau no ka maʻi diabetes type 2.Ua ʻae ʻia ʻo Tirzepatide e ka US Food and Drug Administration (FDA) i Mei 2022 e hoʻomaikaʻi i ka mana glycemic (ma ke kumu ʻai a me ka hoʻomaʻamaʻa) i nā pākeke me ka maʻi maʻi type 2 a ua ʻae ʻia i kēia manawa i ka European Union, Iapana a me nā ʻāina ʻē aʻe.
Ma Iulai 5, ua hoʻolaha ʻo Eli Lilly i kahi haʻawina III SURPASS-CN-MONO e pili ana i ka hoʻopaʻa inoa hoʻokolohua lāʻau lapaʻau a me ka paepae hōʻike ʻike no ka mālama ʻana i nā maʻi maʻi diabetes type 2.ʻO SURPASS-CN-MONO kahi haʻawina i hoʻopaʻa ʻia, pālua-makapō, placebo-controlled phase III i hoʻolālā ʻia e loiloi i ka pono a me ka palekana o ka monotherapy tirzepatide i hoʻohālikelike ʻia me ka placebo i nā poʻe me ka maʻi diabetes type 2.Ua hoʻolālā ka haʻawina e hoʻokomo i 200 mau maʻi me ka maʻi maʻi type 2 ʻaʻole i loaʻa i nā lāʻau antidiabetic i nā lā 90 ma mua o ka kipa 1 (koe naʻe i kekahi mau kūlana lapaʻau, e like me ka maʻi maʻi, ka halemai, a i ʻole ka hōʻoki koho, ka wā pōkole (≤14). nā lā) hoʻohana i ka insulin).
Manaʻo ʻia ka maʻi diabetes type 2 i kēia makahiki
I ka mahina i hala aku nei, ua paʻi ʻia nā hopena o kahi noiʻi SURPASS-AP-Combo ma Mei 25 ma ka puke pai blockbuster Nature Medicine.Ua hōʻike ʻia nā hopena i hoʻohālikelike ʻia me ka glargine insulin, ua hōʻike ʻo Tirzepatide i ka HbA1c maikaʻi aʻe a me ka hoʻohaʻahaʻa kaumaha i ka heluna o nā maʻi maʻi maʻi type 2 ma ka ʻāina ʻo Asia-Pacific (ka nui o Kina): HbA1c hōʻemi a hiki i 2.49% a me ka hoʻēmi kaumaha a hiki i 7.2 kg (9.4%) i nā pule he 40 o ka mālama ʻana, hoʻomaikaʻi nui i nā lipids koko a me ke kahe koko, a maikaʻi ka palekana a me ka hoʻomanawanui.
ʻO ka Phase 3 clinical trial of SURPASS-AP-Combo ka haʻawina mua a Tirzepatide i mālama nui ʻia i nā poʻe maʻi Kina me ka maʻi maʻi type 2, alakaʻi ʻia e Professor Ji Linong o ka Halemai Kanaka o ke Kulanui o Peking.Ua kūlike ʻo SURPASS-AP-Combo me nā hopena o ka ʻimi noiʻi SURPASS honua, e hōʻike hou ana i ka pathophysiology o ka maʻi diabetes i nā maʻi Kina e kūlike me ka poʻe maʻi honua, ʻo ia ke kumu no ka noiʻi like ʻana a me ka hoʻomohala ʻana i nā lāʻau lapaʻau hou. ma Kina a me ka honua, a hāʻawi pū i ke kākoʻo hōʻike paʻa no ka hāʻawi ʻana i nā poʻe maʻi Kina i ka manawa e hoʻohana ai i nā lāʻau lapaʻau maʻi diabetes hou loa a me kā lākou noi lapaʻau ma Kina i ka hiki.
Ka manawa hoʻouna: Sep-18-2023